Trulicity Injection Site Reaction: How Common
The Trulicity label names injection-site as a reported side effect but gives no trial rate for it.
- In the label
- Listed, no rate given
- Label term
- injection-site
Trulicity in brief
The half-life is about 5 days: by 5 d only half is left, and after five half-lives (25 d) about 3% remains.
Taken from the FDA label (DailyMed).
What the Trulicity label gives instead
The Trulicity label does not give an injection site reaction rate. The label identifies five side effects most often and provides their rates.
| Side effect | Placebo | Trulicity 0.75 mg | Trulicity 1.5 mg | More than placebo, 1.5 mg |
|---|---|---|---|---|
| Nausea | 5.3% | 12.4% | 21.1% | +15.8 points |
| Vomiting | 2.3% | 6% | 12.7% | +10.4 points |
| Diarrhea | 6.7% | 8.9% | 12.6% | +5.9 points |
| Abdominal Pain | 4.9% | 6.5% | 9.4% | +4.5 points |
| Decreased Appetite | 1.6% | 4.9% | 8.6% | +7 points |
Source: the Trulicity label (DailyMed).
Comparing other GLP-1s with Trulicity for injection site reaction
Each label covers its own trials, which included different groups of people. Treat this as a rough guide.
| Medicine | Highest rate in the label | Dose group | Placebo | People in the trials |
|---|---|---|---|---|
 Saxenda | 13.9% | all doses | 10.5% | Adults with obesity or overweight (weight management) |
 Zepbound | 8% | 10 mg | 2% | Adults with obesity or overweight (weight management) |
 Ozempic | Listed, no rate given | – | – | – |
 Wegovy | Listed, no rate given | – | – | – |
 Mounjaro | Listed, no rate given | – | – | – |
| Trulicity | Listed, no rate given | – | – | – |
 Victoza | Listed, no rate given | – | – | – |
| Byetta | Listed, no rate given | – | – | – |
 Rybelsus | Not listed | – | – | – |
 Foundayo | Not listed | – | – | – |
Documents used: Zepbound label (DailyMed), Saxenda label (DailyMed).
Taken from the FDA label (DailyMed).
Details stated in the Trulicity label
Here the label names injection site reaction, word for word:
“In the placebo-controlled studies in adults, injection-site reactions (e.g., injection-site rash, erythema) were reported in 0.5% of TRULICITY-treated patients and in 0.0% of placebo-treated patients.”
Taken from the FDA label (DailyMed).